Human/Mouse/Rat MuRF1/TRIM63 Antibody

Detection of Mouse MuRF1/TRIM63 by Western Blot

The qPCR (quantitative real-time PCR) (A) and Western blot analysis (B,C) showed the mRNA (A) and protein (B,C) expressions of TRAF6, MAFBx, and MuRF1 in the TA muscle of mice injected with vehicle (saline, control) or Dex (dexamethasone sodium phosphate in saline, 10 mg/kg) respectively. Data are presented as mean ± SD, n = 9 per animal group, * p < 0.05 versus control. Also shown (B) is a representative Western blot image. GAPDH and tubulin were used as a loading control in qPCR and Western blot analysis. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/15/6/11126), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse MuRF1/TRIM63 by Western Blot

(A) Micrograph showed the morphology of C2C12 myotubes cultured in vehicle (0.1% ethanol-containing plain medium, control) or stimulated by Dex (dexamethasone in vehicle) respectively. Scale bar = 100 μm; (B) Bar graph compared the diameter of C2C12 myotubes cultured in vehicle (control) or stimulated by Dex respectively; and (C,D) Representative Western blot image and Bar graphs displayed the protein expression of TRAF6, MAFBx, MuRF1, and desmin in C2C12 myotubes cultured in vehicle (control) or stimulated by Dex respectively. Tubulin were used as a loading control in Western blot analysis. All data in bar graphs are presented as mean ± SEM (standard error of the mean) from three independent experiments, * p < 0.05 versus control. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/15/6/11126), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse MuRF1/TRIM63 by Western Blot

The qPCR (A) and Western blot analysis (B,C) showed that C2C12 myotubes were transfected with TRAF6-siRNA or control-siRNA; Micrographs (D) showed the morphology of Dex- or vehicle-treated C2C12 myotubes after transfection with TRAF6-siRNA and control-siRNA respectively. Scale bar = 100 μm; Bar graph (E) showed the diameter of Dex- or vehicle-treated C2C12 myotubes after transfection with TRAF6-siRNA and control-siRNA respectively; The qPCR and Western blot analysis showed the mRNA (F) and protein (G,H) expressions of TRAF6, MAFBx, and MuRF1, as well as the protein expression of pFOXO-1 in Dex- or vehicle-treated C2C12 myotubes after transfection with TRAF6-siRNA and control-siRNA respectively. GAPDH and tubulin were used as a loading control in qPCR and Western blot analysis. All data in bar graphs are presented as mean ± SEM from three independent experiments, * p < 0.05. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/15/6/11126), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse MuRF1/TRIM63 by Western Blot

(A) Masson trichrome staining image of the TA muscle from mice co-injected with both Dex and control-siRNA, with both Dex and TRAF6-siRNA, with both vehicle and control-siRNA, or with both vehicle and TRAF6-siRNA, respectively, for 14 days; (B,C) Bar graphs showed the weight (B) and cross sectional area (CSA, C) of the TA muscle from mice co-injected with each of the above four combinations respectively. Scale bar =20 μm; (D–F) The qPCR and Western blot analysis showed the comparison in the mRNA (D) and protein; and (E,F) expression of TRAF6, MAFBx, and MuRF1, as well as the protein expression of pFOXO-1 in the TA muscle of mice co-injected with each of the above four combinations respectively. GAPDH and tubulin were used as a loading control in qPCR and Western blot analysis, respectively. All data in bar graphs are presented as mean ± SD, n = 9 per animal group,* p < 0.05. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/15/6/11126), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of MuRF1/TRIM63 by Western Blot

Muscle atrophy-associated gene expression under iron deficiency in myocytes. (a) mRNA expression of ferroportin, ferritin and N-Myc downstream regulated 1 (NDGR1) in C2C12 myotubes treated with deferoxamine (DFO) (100 μM/mL) and FeSO4 (400 μM /mL) for 24 h. (b) mRNA expression of myogenic and muscle atrophy-associated factors in C2C12 myotubes treated with DFO and FeSO4 for 48 h. Myf5: myogenic factor 5; MyoD: myoblast determination protein 1; MuRF1: muscle RING-finger protein-1. (c) Protein expression of ferroportin, ferritin and NDGR1 in C2C12 myotubes treated with DFO and FeSO4. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. (d) Protein expression of myogenic factors in C2C12 myotubes treated with DFO and FeSO4. (e) Protein expression of muscle atrophy-associated factors in C2C12 myotubes treated with DFO and FeSO4. (f) Expression of myostatin mRNA in C2C12 myotubes treated with different doses of DFO and FeSO4. (g) Expression of myostatin mRNA in C2C12 myotubes treated with DFO in the presence or absence of FeSO4. Data represent mean ± SEM. * p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36139428), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of MuRF1/TRIM63 by Western Blot

Muscle atrophy-associated gene expression under iron deficiency in myocytes. (a) mRNA expression of ferroportin, ferritin and N-Myc downstream regulated 1 (NDGR1) in C2C12 myotubes treated with deferoxamine (DFO) (100 μM/mL) and FeSO4 (400 μM /mL) for 24 h. (b) mRNA expression of myogenic and muscle atrophy-associated factors in C2C12 myotubes treated with DFO and FeSO4 for 48 h. Myf5: myogenic factor 5; MyoD: myoblast determination protein 1; MuRF1: muscle RING-finger protein-1. (c) Protein expression of ferroportin, ferritin and NDGR1 in C2C12 myotubes treated with DFO and FeSO4. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. (d) Protein expression of myogenic factors in C2C12 myotubes treated with DFO and FeSO4. (e) Protein expression of muscle atrophy-associated factors in C2C12 myotubes treated with DFO and FeSO4. (f) Expression of myostatin mRNA in C2C12 myotubes treated with different doses of DFO and FeSO4. (g) Expression of myostatin mRNA in C2C12 myotubes treated with DFO in the presence or absence of FeSO4. Data represent mean ± SEM. * p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36139428), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of MuRF1/TRIM63 by Western Blot

Iron deficiency-induced myostatin regulation by DAX1. (a) Expression of myostatin mRNA in C2C12 myotubes transfected with a nuclear receptor for 48 h. AR: androgen receptor; CAR: constitutive androstane receptor; DAX1: dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region, on chromosome X, gene 1; ER alpha : estrogen receptor alpha ; ERR alpha / beta / gamma : estrogen-related receptor alpha / beta / gamma ; FXR: farnesoid X receptor; GR: glucocorticoid receptor; HNF4 alpha : hepatocyte nuclear factor 4 alpha ; LRH-1: liver receptor homolog-1; LXR alpha : liver X receptor alpha ; PXR: pregnane X receptor; ROR alpha : RAR-related orphan receptor alpha ; SF-1: steroidogenic factor 1; SHP: small heterodimer partner; THR alpha : thyroid hormone receptor alpha ; TR4: testicular receptor 4. (b) Expression of DAX1 mRNA in C2C12 myotubes treated with different doses of deferoxamine (DFO) and FeSO4. (c) Expression of DAX1 mRNA in C2C12 myotubes with DFO in the presence or absence of FeSO4. (d) Adenoviral overexpression of DAX1 and mRNA expression of myogenic and muscle atrophy-associated factors. C2C12 myotubes were infected with an adenovirus expressing DAX1 (Ad-DAX 1) or control vector (Ad-CTL) at 100 multiplicity of infection for 48 h. Myf5: myogenic factor 5; MyoD: myoblast determination protein 1; MuRF1: muscle RING-finger protein-1. (e) Protein expression of muscle atrophy-associated factors in C2C12 myotubes infected with Ad-DAX 1. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. A densitometric analysis of the Western blots is shown in the graph on the right. Data represent mean ± SEM. * p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36139428), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of MuRF1/TRIM63 by Western Blot

Iron deficiency-induced myostatin regulation by DAX1. (a) Expression of myostatin mRNA in C2C12 myotubes transfected with a nuclear receptor for 48 h. AR: androgen receptor; CAR: constitutive androstane receptor; DAX1: dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region, on chromosome X, gene 1; ER alpha : estrogen receptor alpha ; ERR alpha / beta / gamma : estrogen-related receptor alpha / beta / gamma ; FXR: farnesoid X receptor; GR: glucocorticoid receptor; HNF4 alpha : hepatocyte nuclear factor 4 alpha ; LRH-1: liver receptor homolog-1; LXR alpha : liver X receptor alpha ; PXR: pregnane X receptor; ROR alpha : RAR-related orphan receptor alpha ; SF-1: steroidogenic factor 1; SHP: small heterodimer partner; THR alpha : thyroid hormone receptor alpha ; TR4: testicular receptor 4. (b) Expression of DAX1 mRNA in C2C12 myotubes treated with different doses of deferoxamine (DFO) and FeSO4. (c) Expression of DAX1 mRNA in C2C12 myotubes with DFO in the presence or absence of FeSO4. (d) Adenoviral overexpression of DAX1 and mRNA expression of myogenic and muscle atrophy-associated factors. C2C12 myotubes were infected with an adenovirus expressing DAX1 (Ad-DAX 1) or control vector (Ad-CTL) at 100 multiplicity of infection for 48 h. Myf5: myogenic factor 5; MyoD: myoblast determination protein 1; MuRF1: muscle RING-finger protein-1. (e) Protein expression of muscle atrophy-associated factors in C2C12 myotubes infected with Ad-DAX 1. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. A densitometric analysis of the Western blots is shown in the graph on the right. Data represent mean ± SEM. * p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36139428), licensed under a CC-BY license. Not internally tested by R&D Systems.